Not sure if China is right for your treatment? Our comprehensive guide evaluates over 100 conditions across 25 medical specialties — so you can make an informed decision.
China has the world's most comprehensive EGFR-TKI arsenal — over 15 drugs, with fourth-generation agents in the pipeline.
Why China: China leads globally in EGFR-mutant lung cancer treatment. Costs are 1/3 of Western countries, with shorter wait times and access to therapies not yet available elsewhere.
OptiTROP-Lung05 shows sac-TMT + Keytruda outperforms Keytruda alone — a world-first ADC + immunotherapy combination.
Why China: China is the first country to offer this breakthrough combination, with data published in The Lancet. Lower cost and immediate availability.
China developed the world's first approved bispecific ADC for NPC — a therapy that doesn't exist anywhere else.
Why China: Chinese experts lead global NPC treatment. The world-first bispecific ADC (BL-B01D1) is only available in China. NCCN and CSCO guidelines recommend it.
The world's first CAR-T therapy for solid tumors — approved in China for CLDN18.2-positive gastric cancer.
Why China: This is a global first — no other country offers CAR-T for solid tumors. China leads in CLDN18.2-targeted therapies with multiple assets in development.
China accounts for 42.4% of global liver cancer cases — unmatched surgical and interventional experience.
Why China: Chinese surgeons perform the highest volume of liver cancer surgeries globally. GPC3-targeting ADCs are in clinical development with FDA IND approval.
Sac-TMT (TROP2 ADC) is approved in China for breast cancer, with the world's first HER2 bispecific ADC Phase III in HER2-low breast cancer.
Why China: China leads in ADC development with multiple clinical breakthroughs. Costs are significantly lower than Western alternatives.
China has 6 approved CAR-T products for blood cancers, with costs 70–80% lower than the U.S.
Why China: The world's largest CAR-T manufacturing capacity and the most clinical trials globally. Off-the-shelf (allogeneic) options entering clinical trials.
China leads in CLDN18.2-targeted therapies, with CAR-T and ADCs in clinical development.
Why China: While survival remains challenging globally, China offers access to cutting-edge CLDN18.2-targeted therapies not yet available in most countries.
China has EGFR-TKIs specifically designed for brain metastases, including zorifertinib and asandeutertinib.
Why China: Chinese companies have developed drugs specifically for brain metastases — a difficult-to-treat population with few options globally.
China has the highest global incidence of ESCC, with leading surgical and immunotherapy expertise.
Why China: High-volume surgical experience and access to novel immunotherapies and ADCs. Chinese researchers lead global ESCC clinical trials.
China offers access to CLDN18.2-targeted therapies and novel ADCs in clinical development.
Why China: Access to novel targeted therapies in clinical development. High-volume surgical expertise in major cancer centers.
China has high-volume colorectal surgery expertise with robotic-assisted techniques widely available.
Why China: High-volume surgical experience, robotic surgery access, and significant cost savings compared to Western countries.
China performs the highest volume of cardiac surgeries globally, with success rates ≥98%.
Why China: High-volume centers with experienced surgeons. Costs are 1/5–1/8 of U.S. prices. Minimal wait times.
China has extensive experience in TAVR and surgical valve replacement with excellent outcomes.
Why China: High-volume centers with outcomes comparable to the West. Significant cost savings. Growing domestic valve manufacturing.
The world's first non-invasive cardiac radiotherapy robot — a non-surgical treatment for arrhythmias.
Why China: This technology is a global first and only available in China. It offers a non-invasive alternative to catheter ablation.
China performs over 1 million PCI procedures annually — the highest volume globally.
Why China: Unmatched procedural volume and experience. Costs are approximately 1/10 of U.S. prices. State-of-the-art facilities.
China has the world's first bioabsorbable cardiac sealants — devices that dissolve naturally after healing.
Why China: China leads in pediatric interventional cardiology. The bioabsorbable sealant eliminates long-term complications of permanent metal implants.
China's domestically produced ECMO (Lifemotion®) is available at 200+ hospitals nationwide.
Why China: Previously imported only, now domestically produced with EU CE and FDA approvals. Covers 78% of top-tier tertiary hospitals.
China has developed ANGPTL3 monoclonal antibody (SHR-1918) showing 64.2% LDL-C reduction in Phase III.
Why China: A first-in-class therapy for this ultra-rare condition. The LDLR-independent mechanism offers hope where other therapies fail.
HRS-5346 — an oral Lp(a) inhibitor — shows up to 86.3% reduction in Phase II study presented at ESC 2026.
Why China: This is the first oral Lp(a)-specific therapy, offering a convenient alternative to injectable approaches. Highly potent with favorable safety profile.
China has fully magnetically levitated artificial hearts — one of only two such systems approved worldwide.
Why China: Access to advanced LVAD technology at lower cost. However, patients should carefully evaluate long-term management and follow-up options.
China is the world's largest cataract surgery market, with the first domestically developed trifocal toric IOL now available.
Why China: High-volume, experienced surgeons. Premium trifocal toric IOLs at 1/3 of Western prices. Minimal wait times.
China has the highest volume of refractive surgeries globally, with advanced technology and experienced surgeons.
Why China: High-volume experience with state-of-the-art equipment. Costs significantly lower than Western countries. Fast appointment scheduling.
NouvSight001 — the first iPSC-derived cell therapy for RP — has received IND approvals from both NMPA and FDA.
Why China: This is a first-in-class therapy. China offers access to clinical trials with dual regulatory authorization. Still in early-stage clinical development.
China's first ophthalmic gene therapy published in NEJM — demonstrating safety and durable visual improvement.
Why China: The therapy represents a global first for XLRS. Published in NEJM — the gold standard of clinical research. Still in early-stage clinical development.
AHRF gene therapy for LHON demonstrated clinically meaningful visual improvement in Phase I/II trial.
Why China: A novel AAV-based gene therapy targeting the ND4 mutation. Promising early-stage data. One of the few LHON gene therapies in clinical development globally.
China's first domestically developed IRD gene therapy has completed Phase III clinical trials.
Why China: A significant milestone for Chinese gene therapy. The therapy is now poised for NDA submission to NMPA, potentially offering a new option for RPE65-related IRD.
China is developing iPSC-derived RPE cell therapies and novel anti-VEGF biologics for AMD.
Why China: Access to cutting-edge cell therapy clinical trials and cost-effective anti-VEGF treatments. Leading research centers with high patient volume.
hNPC01 iPSC therapy for hemorrhagic stroke — the first of its kind — has completed first-in-human data with 2.5-year follow-up.
Why China: This is a first-in-class therapy for hemorrhagic stroke, a condition with no approved regenerative treatments. FDA IND approval validates quality standards.
China's first 128-channel fully implantable BCI system — offering unprecedented neural signal resolution.
Why China: The 128-channel BCI is one of the most advanced devices globally, now in multi-center clinical trials. Still early-stage but promising.
GA002 — China's first gene therapy for epilepsy — has entered Phase I/II clinical trial.
Why China: A first-in-class gene-editing approach for drug-resistant epilepsy. Still in early-stage clinical development but represents a potential paradigm shift.
iPSC-derived dopamine neuron cell therapy is in Phase I trials at Ruijin Hospital, Shanghai.
Why China: One of the first iPSC-derived therapies for Parkinson's globally. Early-stage but promising. Access to cutting-edge regenerative medicine.
RAG-17 siRNA for SOD1-ALS — first-in-human data published in Nature Medicine.
Why China: China's first siRNA therapy for ALS. Published in Nature Medicine with compelling biomarker data. Early-stage but promising.
LEAPER RNA editing for DMD — the world's first clinical application of RNA editing, published in Cell.
Why China: This is a world-first — no other country has applied RNA editing clinically for DMD. Early-stage but represents a revolutionary approach.
China performs the highest volume of hip replacements globally, with MAKO robotic-assisted surgery widely available.
Why China: High-volume surgeons with 500+ procedures annually. Costs are 1/5 of U.S. prices. Robotic assistance available. Minimal wait times.
China has extensive experience in knee replacement with MAKO robotic-assisted surgery and advanced rehabilitation protocols.
Why China: High-volume centers with outcomes comparable to the West. Costs are 1/5 of U.S. prices. Robotic assistance available. Fast recovery protocols.
China has extensive experience in spinal surgery, including complex deformity correction and minimally invasive techniques.
Why China: High-volume surgical experience with state-of-the-art navigation systems. Significant cost savings. Rapid scheduling.
China has extensive experience in arthroscopic shoulder surgery and sports medicine with robotic-assisted techniques.
Why China: High-volume experience, advanced techniques, and significant cost savings. World-class sports medicine centers.
China has the world's highest volume of trauma cases, with experienced surgeons and innovative biomaterials.
Why China: Unmatched trauma experience and volume. Access to advanced orthopedic biomaterials. Cost-effective treatment.
China has 6 approved CAR-T products for blood cancers — costs are 70–80% lower than the U.S.
Why China: The world's largest CAR-T manufacturing capacity. 6 approved products. Costs $80,000–$120,000 vs $400,000–$500,000 in the U.S. NRDL coverage expanding access.
Multiple universal CAR-T programs with NMPA IND approvals — off-the-shelf, no waiting time.
Why China: China leads in allogeneic CAR-T development with multiple IND approvals. Lower cost and immediate availability compared to autologous CAR-T.
China has multiple iPSC-derived cell therapies in clinical trials for Parkinson's disease, heart failure, and stroke.
Why China: China is a global leader in iPSC clinical translation, with the world's first chemically reprogrammed iPSC-derived islet cells for diabetes and iPSC-derived dopamine neurons for Parkinson's.
QT-019C — the first Chinese universal CAR-T for SLE and myasthenia gravis — has FDA Breakthrough Designation.
Why China: This represents a paradigm shift — CAR-T for autoimmune disease. Still early-stage but with FDA RMAT and Breakthrough Therapy Designation.
China is advancing RNA editing, AAV gene therapy, and CRISPR approaches for rare genetic disorders.
Why China: Multiple first-in-human and first-in-class gene therapies. However, most are still in early-stage clinical development.
China is advancing AAV-based gene therapies for hemophilia A and B.
Why China: Multiple gene therapy programs in clinical development. Access to cutting-edge treatments at lower cost. Still in early-stage trials.
China performs high-volume laparoscopic cholecystectomy with excellent outcomes.
Why China: High-volume experience with minimally invasive techniques. Costs are approximately 1/10 of U.S. prices. Fast scheduling.
China has extensive experience in hernia repair with minimally invasive techniques.
Why China: High-volume experience, excellent outcomes, and significant cost savings compared to Western countries.
China has one of the highest volumes of thyroid surgery globally, with experienced surgeons.
Why China: High-volume experience with excellent outcomes. Significant cost savings. Fast appointment scheduling.
China has extensive experience in minimally invasive gynecological surgery, including hysterectomy and myomectomy.
Why China: High-volume experience with robotic and laparoscopic techniques. Significant cost savings compared to Western countries.
Sub-specialty: Allergic Rhinitis
WAO-certified excellence centers with comprehensive allergy care.
Why China: Peking Union and Zhongshan Third Hospital offer WAO-certified care with immunotherapy and biologic treatments at affordable costs.
Sub-specialty: Asthma & Allergy
Full biologic therapy, drug challenge, and desensitization protocols available.
Why China: Standardized biologic therapies (omalizumab, mepolizumab) and drug challenge testing at leading allergy centers.
Sub-specialty: Immunotherapy
Subcutaneous and sublingual immunotherapy routinely performed.
Why China: Multiple allergen-specific immunotherapy products available at a fraction of Western costs.
Sub-specialty: Urticaria / AD
Specialized clinics for chronic urticaria and eczema.
Why China: Huashan Hospital has strong history in atopic dermatitis research and treatment with cost-effective biologic options.
Sub-specialty: Psoriasis
Biologics targeting IL-17 and IL-23 are widely available.
Why China: Leading hospitals offer comprehensive biologic therapy management. HKU-Shenzhen manages 500+ psoriasis cases monthly.
Sub-specialty: Vitiligo
308nm excimer laser and epidermal grafting are standard treatments.
Why China: Leading hospitals offer comprehensive vitiligo treatment programs with phototherapy and surgical options at affordable costs.
Sub-specialty: Atopic Dermatitis
HKU-Shenzhen manages 400+ AD cases monthly with international protocols.
Why China: Biologic therapies including dupilumab are routinely prescribed at lower costs.
Sub-specialty: Aesthetic
State-of-the-art laser treatments at 1/3 of Western prices.
Why China: HKU-Shenzhen guided by internationally renowned laser dermatologists. Significant cost savings.
Sub-specialty: STI
Standardized diagnosis and treatment protocols well-established.
Why China: Competent care exists, but international patients typically prefer local treatment for STI care.
Sub-specialty: Diabetes
China has the world's largest diabetic population with comprehensive MMC programs.
Why China: MMC network and integrated TCM-Western medicine approaches with affordable care.
Sub-specialty: Thyroid
Comprehensive thyroid nodule evaluation and management.
Why China: Peking Union offers integrated TCM-Western medicine clinics for thyroid conditions.
Sub-specialty: Osteoporosis
Comprehensive bone health assessment and management.
Why China: Cost-effective DXA screening and medication at significant savings.
Sub-specialty: Adrenal & Pituitary
Peking Union is a national authority in this area.
Why China: Exceptional expertise exists, but these are relatively rare disorders with limited international patient demand.
Sub-specialty: Endoscopy
ESD, EUS, and ERCP routinely performed by experienced specialists.
Why China: High-volume screening with expert pathologists at a fraction of Western costs.
Sub-specialty: IBD
Tongji Hospital is an IBDQCC-certified regional center.
Why China: Comprehensive biologic therapy management with significant cost savings.
Sub-specialty: IgA Nephropathy
China is a global leader in IgA nephropathy research and treatment.
Why China: Peking University First Hospital's IgA research has been cited in international guidelines.
Sub-specialty: Lupus Nephritis / CKD
Tongji Hospital conducts stem cell research for CKD management.
Why China: Extensive experience with complex lupus nephritis and CKD cases with affordable treatment options.
Sub-specialty: Dialysis
China has the world's largest dialysis population with extensive experience.
Why China: High-quality dialysis at significantly lower cost than Western countries.
Sub-specialty: Obstetrics
Pregnancy and delivery services involve complex legal and logistical considerations.
Why Not: Cross-border delivery involves visa policies, newborn citizenship, birth certificate issuance, and postpartum care — not recommended for international patients.
Sub-specialty: Gynecologic Oncology
Gynecologic cancer surgery is well-established with experienced surgeons.
Why China: Competent care exists, but international patients often prefer established gynecologic oncology centers in the U.S., Europe, or Japan.
Sub-specialty: ART
High-quality ART services at lower costs.
Why Consider: Legal and ethical issues regarding embryo status and cross-border surrogacy make this complex for international patients.
Sub-specialty: Otology
Xinhua Hospital has China's highest-volume cochlear implant program.
Why China: World-class cochlear implant surgery at a fraction of Western costs with excellent outcomes.
Sub-specialty: Rhinology & Laryngology
Xinhua Hospital has nationally renowned rhinology and laryngology programs.
Why China: Highly experienced surgeons with specialized voice clinics at affordable costs.
Sub-specialty: Head & Neck
Comprehensive head and neck cancer services.
Why China: Multi-disciplinary head and neck oncology care with significant cost savings.
Sub-specialty: Ankle Replacement
3D-printed total ankle replacement with surgical time reduced from 3 hours to 85 minutes.
Why China: Advanced 3D-printed implants and significantly lower costs.
Sub-specialty: Foot & Ankle
High-volume trauma and sports medicine programs.
Why China: Massive surgical volume, advanced 3D-printed implants, and cost-effective care.
Sub-specialty: Psychiatry & Psychology
Top psychiatric hospitals provide bilingual evaluations for major mental disorders.
Why Consider: Language and cultural barriers are significant. Translation cannot fully substitute for direct therapeutic communication.
Sub-specialty: Pulmonary Disease
Guangzhou Medical University ranks #1 in pulmonology for 15 consecutive years.
Why China: China has 100 million COPD and 40 million asthma patients — unparalleled clinical experience. Affordable biologics and rapid access.
Sub-specialty: Interventional
China is a global leader in advanced interventional pulmonology techniques.
Why China: High-volume experience with bronchoscopy, EBUS, and therapeutic interventions at lower costs.
Sub-specialty: Rheumatic Disease
Peking Union has been ranked #1 in rheumatology for 15 consecutive years.
Why China: TCM-integrated RA treatment with Chinese experts co-authoring international guidelines. Affordable biologics.
Sub-specialty: Sleep Apnea
Beijing Tsinghua Changgung Hospital has a nationally leading sleep medicine center.
Why China: Multidisciplinary sleep medicine programs with affordable sleep studies and CPAP therapy.
Sub-specialty: Urology
Da Vinci robotic surgery widely available; China has one of the highest stone disease rates globally.
Why China: Affordable robotic surgery, extensive experience with PCNL/HoLEP, and significant cost savings.
Sub-specialty: Pelvic Floor
China has established national-level pelvic floor medical centers with international training programs.
Why China: Advanced pelvic floor reconstruction surgery at significantly lower costs, with comprehensive rehabilitation programs.
Sub-specialty: Acupuncture
Sanya TCM Hospital has served over 130,000 international visitors from 40+ countries.
Why China: China is the birthplace of acupuncture with the world's most experienced practitioners.
Sub-specialty: Tuina
Tuina is widely available for musculoskeletal and stress-related conditions.
Why China: Sanya and other wellness destinations offer authentic TCM therapeutic massage.
Sub-specialty: Herbal Medicine
Herbal medicine is most sought after for chronic conditions, oncology, and metabolic disorders.
Why China: Authentic herbal medicine from the source, with qualified practitioners and quality-controlled herbs.
Sub-specialty: TCM Orthopedics
TCM bone-setting techniques for fractures, dislocations, and soft tissue injuries.
Why China: Wangjing Hospital is a national leader in TCM orthopedics.
Sub-specialty: TCM Specialties
TCM has unique approaches to menstrual disorders, cancer supportive care, psoriasis, and eczema.
Why China: Leading institutions with nationally recognized TCM traditions (Zhao Bingnan lineage, Guang'anmen TCM oncology).
Sub-specialty: TCM Wellness
Sanya International TCM Wellness Center offers an integrated "medical-care-wellness" destination experience.
Why China: Sanya TCM Hospital has a dedicated "Preventive Medicine Center" — a key TCM wellness destination.
China offers comprehensive VIP health checkup packages at a fraction of Western prices.
Why China: Comprehensive full-body checkups ($300–$800) vs $5,000–$10,000 in the U.S. Fast scheduling with English-speaking coordinators. State-of-the-art equipment.
China offers high-quality dental implant procedures at 30–50% of Western costs.
Why China: Experienced dentists with international training. High-quality materials. Significant cost savings. Fast appointment scheduling.
China offers world-class TCM integrative therapies combined with Western medicine.
Why China: Access to the world's leading TCM practitioners. Integrative approaches combining acupuncture, herbal medicine, and Western treatments. Cost-effective.
China's early cancer screening programs are developing but not yet at the level of leading countries.
Why Not: For early detection of rare or complex cancers, leading centers in the U.S., Japan, and Germany offer more advanced screening protocols and specialized expertise.
While China has excellent neurosurgeons, high-risk procedures near critical brain structures require ultra-specialized expertise.
Why Not: For the most complex neurosurgical cases, leading centers in Germany, the U.S., and Japan offer the highest level of specialized expertise and intraoperative technologies.
For ultra-rare bone or joint conditions, specialized centers in the U.S. or Europe may offer more targeted expertise.
Why Not: While China handles common orthopedic conditions exceptionally well, ultra-rare conditions may be better served at international centers of excellence.
While China has the technical capability, organ transplantation for international patients faces significant challenges.
Why Not: International patients face legal and ethical barriers to organ transplantation in China. Organs are prioritized for Chinese citizens. Seek transplantation in countries with established international programs.
No conditions found matching your search. Try adjusting your search term or filter.
Our team of international patient coordinators can help you evaluate your specific condition and recommend the best treatment options in China.
Book a Free Consultation →